International Urology and Nephrology

, Volume 48, Issue 10, pp 1649–1655 | Cite as

A novel anticancer agent icaritin inhibited proinflammatory cytokines in TRAMP mice

  • Jimeng Hu
  • Tian Yang
  • Hua Xu
  • Mengbo Hu
  • Hui Wen
  • Haowen Jiang
Urology - Original Paper
First Online:
Received:
Accepted:
  • 236 Downloads

Abstract

Purpose

We aimed to investigate whether icaritin (ICT) would inhibit serum proinflammatory cytokines and postpone prostate cancer (PCa) development and progression in both normal diet and high-fat diet (HFD) transgenic adenocarcinoma mouse prostate (TRAMP) mice.

Methods

TRAMP mice were randomly divided into four groups: normal diet with/without ICT group and HFD with/without ICT group. Each TRAMP mouse received intraperitoneal injection of ICT solution at the dose of 30 mg/kg 5 times per week.

Results

ICT treatment could significantly increase the survival when compared with those in normal diet group (P = 0.015, log-rank test) and HFD group (P = 0.009, log-rank test). Proinflammatory cytokine levels, including IL-1α, IL-1β, IL-6, and TNF-α, were decreased more or less in ICT-treated TRAMP mice. Moreover, significant higher inflammation scores were detected in normal diet group and HFD group compared with their relevant ICT treatment groups (P = 0.026 and P = 0.006, respectively). Meanwhile, the incidences of well-differentiated tumor tissue in two ICT treatment groups (39.13 and 31.82 %) were moderately higher than control groups (29.41 and 20.00 %, respectively), though no significant difference was observed.

Conclusions

Taken together, our findings indicate that ICT could inhibit the development and progression of PCa in TRAMP mice via inhibiting proinflammatory cytokines.

Keywords

Prostate cancer TRAMP Icaritin Proinflammatory cytokines High-fat diet 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This study was sponsored by the National Natural Science Foundation of China (81272835).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable International, National, and/or Institutional Guidelines for the care and use of animals were followed.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29CrossRefPubMedGoogle Scholar
  2. 2.
    Hsing AW, Tsao L, Devesa SS (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60–67CrossRefPubMedGoogle Scholar
  3. 3.
    Fleshner N, Bagnell PS, Klotz L, Venkateswaran V (2004) Dietary fat and prostate cancer. J Urol 171:S19–S24CrossRefPubMedGoogle Scholar
  4. 4.
    Lophatananon A, Archer J, Easton D et al (2010) Dietary fat and early-onset prostate cancer risk. Br J Nutr 103:1375–1380CrossRefPubMedGoogle Scholar
  5. 5.
    Xu H, Hu MB, Bai PD, Zhu WH, Ding Q, Jiang HW (2014) Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer development and progression? Int Urol Nephrol 46:2327–2334CrossRefPubMedGoogle Scholar
  6. 6.
    Xu H, Jiang HW, Ding Q (2015) Insulin-Like growth factor 1 related pathways and high-fat diet promotion of transgenic adenocarcinoma mouse prostate (TRAMP) cancer progression. Actas Urol Esp 39:161–168CrossRefPubMedGoogle Scholar
  7. 7.
    Xu H, Hu MB, Bai PD et al (2015) Proinflammatory cytokines in prostate cancer development and progression promoted by high-fat diet. Biomed Res Int 2015:249741PubMedPubMedCentralGoogle Scholar
  8. 8.
    Wo YB, Zhu DY, Hu Y, Wang ZQ, Liu J, Lou YJ (2008) Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J Cell Biochem 103:1536–1550CrossRefPubMedGoogle Scholar
  9. 9.
    Wang Z, Wang H, Wu J et al (2009) Enhanced co-expression of beta-tubulin III and choline acetyltransferase in neurons from mouse embryonic stem cells promoted by icaritin in an estrogen receptor-independent manner. Chem Biol Interact 179:375–385CrossRefPubMedGoogle Scholar
  10. 10.
    Li Q, Huai L, Zhang C et al (2013) Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3 K/AKT signal pathways. Int J Hematol 97:617–623CrossRefPubMedGoogle Scholar
  11. 11.
    Zhu S, Wang Z, Li Z et al (2015) Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget 6:10460–10472CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wang ZQ, Lou YJ (2004) Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol 504:147–153CrossRefPubMedGoogle Scholar
  13. 13.
    Li S, Priceman SJ, Xin H et al (2013) Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS ONE 8:e81657CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Huang X, Zhu D, Lou Y (2007) A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol 564:26–36CrossRefPubMedGoogle Scholar
  15. 15.
    Greenberg NM, DeMayo F, Finegold MJ et al (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92:3439–3443CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y (2010) Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70:745–754CrossRefPubMedGoogle Scholar
  17. 17.
    Hara T, Miyazaki J, Araki H et al (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149–153PubMedGoogle Scholar
  18. 18.
    Sun F, Indran IR, Zhang ZW et al (2015) A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. Carcinogenesis 36:757–768CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gingrich JR, Greenberg NM (1996) A transgenic mouse prostate cancer model. Toxicol Pathol 24:502–504CrossRefPubMedGoogle Scholar
  20. 20.
    Gingrich JR, Barrios RJ, Morton RA et al (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56:4096–4102PubMedGoogle Scholar
  21. 21.
    Kwon OJ, Zhang L, Ittmann MM, Xin L (2014) Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci USA 111:E592–E600CrossRefPubMedGoogle Scholar
  22. 22.
    Elkahwaji JE, Hauke RJ, Brawner CM (2009) Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer 101:1740–1748CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    De Marzo AM, Platz EA, Sutcliffe S et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Xu H, Ding Q, Jiang HW (2014) Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk. Asian Pac J Cancer Prev 15:8741–8747CrossRefPubMedGoogle Scholar
  25. 25.
    Kutikov A, Makhov P, Golovine K et al (2011) Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 78:968.e7–e11Google Scholar
  26. 26.
    Nguyen DP, Li J, Tewari AK (2014) Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int 113:986–992CrossRefPubMedGoogle Scholar
  27. 27.
    Wallner L, Dai J, Escara-Wilke J et al (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 66:3087–3095CrossRefPubMedGoogle Scholar
  28. 28.
    Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90:2312–2316PubMedPubMedCentralGoogle Scholar
  29. 29.
    Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4:1743–1748PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Jimeng Hu
    • 1
  • Tian Yang
    • 1
  • Hua Xu
    • 1
  • Mengbo Hu
    • 1
  • Hui Wen
    • 1
  • Haowen Jiang
    • 1
  1. 1.Department of Urology, Huashan HospitalFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations